Cardiff Oncology, Inc. - Form 8-K Summary
Business Context and Reporting Period
Cardiff Oncology, Inc. (CRDF) filed this Current Report on Form 8-K on December 10, 2024. The filing discloses the entry into a material definitive agreement regarding a public equity offering.
Key Financial Metrics and Transaction Details
- Transaction Type: Underwritten public offering of common stock.
- Shares Issued: 15,384,619 shares.
- Offering Price: $2.60 per share.
- Gross Proceeds: Approximately $40 million (before underwriting discounts, commissions, and offering expenses).
- Net Proceeds Usage: Funding clinical costs for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC), working capital, and general corporate purposes.
- Closing Date: Expected on or about December 11, 2024.
Material Changes and Agreements
The Company entered into an Underwriting Agreement with TD Securities (USA) LLC as representative. The offering is conducted pursuant to an effective shelf registration statement on Form S-3 (File No. 333-264148). The filing text does not provide specific prior period financial metrics (revenue, profit, cash flow) as this is a transactional report rather than a periodic financial statement.
Management Commentary, Risks, and Lock-Up Provisions
- Lock-Up Agreement: The Company, its directors, and executive officers have agreed not to sell or transfer any shares of Common Stock for 90 days from the date of the Underwriting Agreement without written consent from the Representative.
- Legal Opinion: An opinion regarding the legality of the issuance was provided by Sheppard, Mullin, Richter & Hampton LLP.
- Risks: The offering is subject to customary closing conditions. The description of the agreement is qualified by reference to the full Underwriting Agreement.
Key Facts for Investor Verification
- Verify the final closing date and actual net proceeds after deducting underwriting discounts and expenses.
- Confirm the specific allocation of funds between the onvansertib clinical trial and general working capital.
- Monitor the 90-day lock-up expiration date for potential insider selling activity.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification obligations and termination provisions.